Physician profile
Daniel Hyman
NPI 1083292783
$8,221.37
in general payments reported to CMS, 2019-2025
26 companies · $1,913 in 2025
The $1,913 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $565 · 2023: $3,262 · 2024: $2,481 · 2025: $1,913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,863 · Travel and Lodging: $1,681 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,862.98 |
| Travel and Lodging | $1,680.82 |
| Education | $112.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,357.69 | 2022-2025 | |
| Lilly USA, LLC | $683.55 | 2022-2025 | Olumiant, Ebglyss, Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $574.90 | 2023-2025 | Spevigo |
| Genzyme Corporation | $473.24 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $437.05 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $420.71 | 2023-2025 | Sotyktu |
| Janssen Biotech, INC. | $378.63 | 2024-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $321.87 | 2024-2025 | Zoryve |
| Kyowa Kirin, INC. | $313.75 | 2022-2024 | Poteligeo |
| Galderma Laboratories, L.P. | $303.22 | 2024-2025 | Nemluvio, Aklief |
| Ucb, INC. | $246.07 | 2024-2025 | Bimzelx |
| Incyte Corporation | $240.33 | 2023-2024 | Opzelura |
| Janssen Scientific Affairs, LLC | $214.86 | 2024-2025 | Tremfya |
| Dermavant Sciences, INC. | $179.45 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $175.31 | 2022-2023 | Targretin, Siliq |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $144.35 | 2024 | Uvadex |
| Krystal Biotech INC | $117.32 | 2023 | Vyjuvek |
| Novartis Pharmaceuticals Corporation | $106.10 | 2025 | |
| Amgen INC. | $102.92 | 2025 | Otezla |
| Pfizer INC. | $102.38 | 2022-2025 | |
| Biofrontera INC. | $100.65 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $98.44 | 2022 | |
| Organogenesis INC. | $55.58 | 2025 | Affinity |
| Organon LLC | $30.70 | 2025 | |
| Leo Pharma INC. | $29.13 | 2025 | Anzupgo |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hyman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.